

Raymond U Osarogiagbon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2120828/publications.pdf>

Version: 2024-02-01

82
papers

2,207
citations

201674

27
h-index

265206

42
g-index

83
all docs

83
docs citations

83
times ranked

1570
citing authors

#	ARTICLE	IF	CITATIONS
1	Number of Lymph Nodes Associated With Maximal Reduction of Long-Term Mortality Risk in Pathologic Node-Negative Nonâ€“Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2014, 97, 385-393.	1.3	130
2	â€œWhen Offered to Participateâ€ A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2021, 113, 244-257.	6.3	116
3	Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Nonâ€“Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results Database. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1798-1806.	1.1	110
4	Incomplete Intrapulmonary Lymph Node Retrieval After Routine Pathologic Examination of Resected Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2823-2828.	1.6	102
5	Association of Pathologic Nodal Staging Quality With Survival Among Patients With Nonâ€“Small Cell Lung Cancer After Resection With Curative Intent. <i>JAMA Oncology</i> , 2018, 4, 80.	7.1	94
6	Nonexamination of Lymph Nodes and Survival After Resection of Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2013, 96, 1178-1189.	1.3	85
7	Objective Review of Mediastinal Lymph Node Examination in a Lung Cancer Resection Cohort. <i>Journal of Thoracic Oncology</i> , 2012, 7, 390-396.	1.1	73
8	Persistent Disparity: Socioeconomic Deprivation and Cancer Outcomes in Patients Treated in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2021, 39, 1339-1348.	1.6	62
9	Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2016, 102, 448-453.	1.3	59
10	Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa034.	2.9	59
11	Quality of surgical resection for nonsmall cell lung cancer in a US metropolitan area. <i>Cancer</i> , 2011, 117, 134-142.	4.1	58
12	Survival Implications of Variation in the Thoroughness of Pathologic Lymph Node Examination in American College of Surgeons Oncology Group Z0030 (Alliance). <i>Annals of Thoracic Surgery</i> , 2016, 102, 363-369.	1.3	55
13	Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Nonâ€“Small Cell Lung Cancer in the U.S. National Cancer Data Base. <i>Journal of Thoracic Oncology</i> , 2016, 11, e5-e16.	1.1	55
14	The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 801-809.	1.1	49
15	Ruralâ€“Urban Disparities in Cancer Outcomes: Opportunities for Future Research. <i>Journal of the National Cancer Institute</i> , 2022, 114, 940-952.	6.3	46
16	Causes and Consequences of Deviation from Multidisciplinary Care in Thoracic Oncology. <i>Journal of Thoracic Oncology</i> , 2011, 6, 510-516.	1.1	44
17	Use of a Surgical Specimen-Collection Kit to Improve Mediastinal Lymph-Node Examination of Resectable Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1276-1282.	1.1	44
18	Outcome of Surgical Resection for Pathologic N0 and Nx Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 191-196.	1.1	41

#	ARTICLE	IF	CITATIONS
19	Pathologic Lymph Node Staging Practice and Stage-Predicted Survival After Resection of Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2011, 91, 1486-1492.	1.3	39
20	Beyond Margin Status: Population-Based Validation of the Proposed International Association for the Study of Lung Cancer Residual Tumor Classification Recategorization. <i>Journal of Thoracic Oncology</i> , 2020, 15, 371-382.	1.1	39
21	'One-stop shop': lung cancer patients' and caregivers' perceptions of multidisciplinary care in a community healthcare setting. <i>Translational Lung Cancer Research</i> , 2015, 4, 456-64.	2.8	37
22	Early-Stage NSCLC: Advances in Thoracic Oncology 2018. <i>Journal of Thoracic Oncology</i> , 2019, 14, 968-978.	1.1	35
23	Preoperative Evaluation of Lung Cancer in a Community Health Care Setting. <i>Annals of Thoracic Surgery</i> , 2015, 100, 394-400.	1.3	32
24	Survival After Mediastinal Node Dissection, Systematic Sampling, or Neither for Early Stage NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1670-1681.	1.1	32
25	Lung Cancer Diagnosed Through Screening, Lung Nodule, and Neither Program: A Prospective Observational Study of the Detecting Early Lung Cancer (DELUGE) in the Mississippi Delta Cohort. <i>Journal of Clinical Oncology</i> , 2022, 40, 2094-2105.	1.6	32
26	Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216). <i>JAMA Oncology</i> , 2022, 8, 717.	7.1	32
27	Survival impact of postoperative therapy modalities according to margin status in non-small cell lung cancer patients in the United States. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 661-672.e10.	0.8	31
28	Prognostic Value of National Comprehensive Cancer Network Lung Cancer Resection Quality Criteria. <i>Annals of Thoracic Surgery</i> , 2017, 103, 1557-1565.	1.3	31
29	Audit of Lymphadenectomy in Lung Cancer Resections Using a Specimen Collection Kit and Checklist. <i>Annals of Thoracic Surgery</i> , 2015, 99, 421-427.	1.3	29
30	Invasive mediastinal staging for resected non-small cell lung cancer in a population-based cohort. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 158, 1220-1229.e2.	0.8	29
31	The impact of a novel lung gross dissection protocol on intrapulmonary lymph node retrieval from lung cancer resection specimens. <i>Annals of Diagnostic Pathology</i> , 2014, 18, 220-226.	1.3	25
32	Deploying Team Science Principles to Optimize Interdisciplinary Lung Cancer Care Delivery: Avoiding the Long and Winding Road to Optimal Care. <i>Journal of Oncology Practice</i> , 2016, 12, 983-991.	2.5	24
33	Comment on the Proposals for the Revision of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1612-1614.	1.1	24
34	Progress in the Management of Early-Stage Non-small Cell Lung Cancer in 2017. <i>Journal of Thoracic Oncology</i> , 2018, 13, 767-778.	1.1	24
35	County-Level Variations in Receipt of Surgery for Early-Stage Non-small Cell Lung Cancer in the United States. <i>Chest</i> , 2020, 157, 212-222.	0.8	24
36	Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 66-78.	3.8	23

#	ARTICLE	IF	CITATIONS
37	Rurality, Stage-Stratified Use of Treatment Modalities, and Survival of Non-small Cell Lung Cancer. <i>Chest</i> , 2020, 158, 787-796.	0.8	19
38	eSyM: An Electronic Health Recordâ€“Integrated Patient-Reported Outcomesâ€“Based Cancer Symptom Management Program Used by Six Diverse Health Systems. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100137.	2.1	19
39	Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM. <i>Journal of Thoracic Disease</i> , 2012, 4, 214-6.	1.4	18
40	Making the Evidentiary Case for Universal Multidisciplinary Thoracic Oncologic Care. <i>Clinical Lung Cancer</i> , 2018, 19, 294-300.	2.6	17
41	Implementing effective and sustainable multidisciplinary clinical thoracic oncology programs. <i>Translational Lung Cancer Research</i> , 2015, 4, 448-55.	2.8	17
42	Towards optimal pathologic staging of resectable non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2013, 2, 364-71.	2.8	17
43	Effectiveness of Implemented Interventions on Pathologic Nodal Staging of Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018, 106, 228-234.	1.3	16
44	Improving lung cancer outcomes by improving the quality of surgical care. <i>Translational Lung Cancer Research</i> , 2015, 4, 424-31.	2.8	16
45	Dual Intervention to Improve Pathologic Staging of Resectable Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2013, 96, 1975-1981.	1.3	15
46	Risk-Adjusted Margin Positivity Rate as a Surgical Quality Metric for Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2017, 104, 1161-1170.	1.3	15
47	Outcomes After Use of a Lymph Node Collection Kit for Lung Cancer Surgery: A Pragmatic, Population-Based, Multi-Institutional, Staggered Implementation Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 630-642.	1.1	15
48	Pragmatic trial of a multidisciplinary lung cancer care model in a community healthcare setting: study design, implementation evaluation, and baseline clinical results. <i>Translational Lung Cancer Research</i> , 2018, 7, 88-102.	2.8	14
49	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCOâ€“Friends of Cancer Research Prior Therapies Work Group. <i>Clinical Cancer Research</i> , 2021, 27, 2408-2415.	7.0	14
50	Evolution in the Surgical Care of Patients With Nonâ€“Small Cell Lung Cancer in the Mid-South Quality of Surgical Resection Cohort. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2017, 29, 91-101.	0.6	12
51	Improving the pathologic evaluation of lung cancer resection specimens. <i>Translational Lung Cancer Research</i> , 2015, 4, 432-7.	2.8	12
52	Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer: a systematic review with meta-analysis. <i>Translational Lung Cancer Research</i> , 2016, 5, 258-264.	2.8	11
53	Overcoming the Implementation Gap in Multidisciplinary Oncology Care Programs. <i>Journal of Oncology Practice</i> , 2016, 12, 888-891.	2.5	11
54	â€œLike heart valve clinic, it probably saves lives, butâ€“ Who has time for that?â€“The challenge of disseminating multidisciplinary cancer care in the <sc>United States</sc>. <i>Cancer</i> , 2018, 124, 3634-3637.	4.1	10

#	ARTICLE	IF	CITATIONS
55	Institutional-Level Differences in Quality and Outcomes of Lung Cancer Resections in the United States. <i>Chest</i> , 2021, 159, 1630-1641.	0.8	10
56	Comparative Effectiveness of a Lymph Node Collection Kit Versus Heightened Awareness on Lung Cancer Surgery Quality and Outcomes. <i>Journal of Thoracic Oncology</i> , 2021, 16, 774-783.	1.1	10
57	Implementation of patient-reported outcomes for symptom management in oncology practice through the SIMPRO research consortium: a protocol for a pragmatic type II hybrid effectiveness-implementation multi-center cluster-randomized stepped wedge trial. <i>Trials</i> , 2022, 23, .	1.6	9
58	Size and histologic characteristics of lymph node material retrieved from tissue discarded after routine pathologic examination of lung cancer resection specimens. <i>Annals of Diagnostic Pathology</i> , 2014, 18, 136-139.	1.3	8
59	Survival Before and After Direct Surgical Quality Feedback in a Population-Based Lung Cancer Cohort. <i>Annals of Thoracic Surgery</i> , 2019, 107, 1487-1493.	1.3	8
60	The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities. <i>Journal of Thoracic Oncology</i> , 2021, 16, 897-901.	1.1	8
61	Computer modeling of lung cancer diagnosis-to-treatment process. <i>Translational Lung Cancer Research</i> , 2015, 4, 404-14.	2.8	8
62	Volume-Based Care Regionalization: Pitfalls and Challenges. <i>Journal of Clinical Oncology</i> , 2020, 38, 3465-3467.	1.6	7
63	Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected NSCLC in a High Mortality Area of the United States. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1663-1671.	1.1	7
64	“All boats will rise”: Physicians’ perspectives on multidisciplinary lung cancer care in a community-based hospital setting. <i>Supportive Care in Cancer</i> , 2020, 28, 1765-1773.	2.2	6
65	Survival Impact of an Enhanced Multidisciplinary Thoracic Oncology Conference in a Regional Community Health Care System. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100203.	1.1	6
66	Reducing Bottlenecks to Improve the Efficiency of the Lung Cancer Care Delivery Process: A Process Engineering Modeling Approach to Patient-Centered Care. <i>Journal of Medical Systems</i> , 2018, 42, 16.	3.6	5
67	Management of screening-detected stage I lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, E1416-E1419.	1.4	4
68	The Relative Survival Impact of Guideline-Concordant Clinical Staging and Stage-Appropriate Treatment of Potentially Curable Non-Small Cell Lung Cancer. <i>Chest</i> , 2022, 162, 242-255.	0.8	4
69	Prospective Comparative Effectiveness Trial of Multidisciplinary Lung Cancer Care Within a Community-Based Health Care System. <i>JCO Oncology Practice</i> , 2023, 19, e15-e24.	2.9	4
70	Strategic approach to minimally invasive mediastinal nodal staging—a brave new world?. <i>Lancet Respiratory Medicine</i> , 2016, 4, 926-927.	10.7	2
71	Achieving Better Quality of Lung Cancer Care. , 2018, , 167-182.		2
72	Impact of a Lymph Node Specimen Collection Kit on the Distribution and Survival Implications of the Proposed Revised Lung Cancer Residual Disease Classification: A Propensity-Matched Analysis. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100161.	1.1	2

#	ARTICLE	IF	CITATIONS
73	Reply. Annals of Thoracic Surgery, 2015, 100, 768-769.	1.3	1
74	Response to Clinical Thoughts on Mediastinal Node Management in Early-Stage Lung Cancer. Journal of Thoracic Oncology, 2020, 15, e185-e186.	1.1	1
75	Physiciansâ€™ perspectives on multidisciplinary (MD) lung cancer care in a community-based hospital setting.. Journal of Clinical Oncology, 2016, 34, 6544-6544.	1.6	1
76	Pragmatic study of a lymph node (LN) collection kit for non-small cell lung cancer (NSCLC) resection.. Journal of Clinical Oncology, 2018, 36, 8502-8502.	1.6	1
77	Measuring improvement in populations: implementing and evaluating successful change in lung cancer care. Translational Lung Cancer Research, 2015, 4, 373-84.	2.8	1
78	Improving post-resection risk stratification in non-small cell lung cancer: â€˜wit, whither wander you?â€™. Journal of Thoracic Disease, 2016, 8, 2315-2318.	1.4	0
79	Reply. Annals of Thoracic Surgery, 2016, 101, 1628-1629.	1.3	0
80	Barriers to web-based symptom management systems (web-SyMS).. Journal of Clinical Oncology, 2021, 39, 6545-6545.	1.6	0
81	The future in the instant: The lung adenocarcinoma classification as a predictor of future adverse events. Lung Cancer, 2021, 155, 191-192.	2.0	0
82	Response to: â€œLymph Node Dissection for Nonâ€œSmall-Cell Lung Cancer at Whose Discretion?â€œ. Journal of Thoracic Oncology, 2021, 16, e36-e37.	1.1	0